Crossmark

Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke

Crossref DOI link: https://doi.org/10.1038/nrneurol.2016.125

Published Online: 2016-09-12

Published Print: 2016-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Esenwa, Charles C.

Elkind, Mitchell S.
License Information

Text and Data Mining valid from 2016-09-12
More Information

Article History

First Online: 12 September 2016

Competing interests

: M.S.E received research support from the Bristol-Myers Squibb–Sanofi Partnership and diaDexus, Inc.; royalties from UpToDate for chapters related to cryptogenic stroke and hemicraniectomy; receives compensation for providing consultative services for Biotelemetry (Cardionet), the Bristol-Myers Squibb–Pfizer Partnership, Boehringer–Ingelheim, and the Sanofi–Regeneron Partnership; serves as the lead Principal Investigator for a Biogen IDEC study of Tysabri<sup>®</sup> and stroke; and has given expert legal opinions on behalf of Merck (NuvaRing<sup>®</sup> and stroke litigation), BMS-Sanofi Pharmaceutical Partnership (clopidogrel and stroke litigation), and Hi-Tech Pharmaceuticals (dimethylamylamine and stroke litigation). C.C.E. declares no competing interests.